Cytogenetics in multiple myeloma: a multicenter study of 24 patients with t(11;14)(q13;q32) or its variant.

[1]  International System for Human Cytogenetic Nomenclature , 2020, Definitions.

[2]  L. Zech,et al.  2 translocations, t(11;14) and t(1;6), in a patient with plasma cell leukaemia and 2 populations of plasma cells. , 2009, Scandinavian journal of haematology.

[3]  T. Facon,et al.  MULTIPLE MYELOMA: ALMOST ALL PATIENTS ARE CYTOGENETICALLY ABNORMAL , 1996, British journal of haematology.

[4]  D. Gerhard,et al.  Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. , 1996, Blood.

[5]  M. Taniwaki,et al.  Non-random chromosomal rearrangements and their implications in clinical features and outcome of multiple myeloma and plasma cell leukemia. , 1996, Leukemia & lymphoma.

[6]  C. Mecucci,et al.  Molecular breakpoints of t(11;14)(q13;q32) in multiple myeloma. , 1995, Cancer genetics and cytogenetics.

[7]  B. Quesnel,et al.  The retinoblastoma gene (RB-1) status in multiple myeloma: a report on 35 cases. , 1995, Leukemia & lymphoma.

[8]  M. Nair,et al.  Nonrandom karyotype abnormalities in 36 multiple myeloma patients. , 1995, Cancer genetics and cytogenetics.

[9]  B. Barlogie,et al.  Cytogenetic findings in 200 patients with multiple myeloma. , 1995, Cancer genetics and cytogenetics.

[10]  C. Louvet,et al.  Cytogenetic study in multiple myeloma at diagnosis: comparison of two techniques , 1995, British journal of haematology.

[11]  J. Mary,et al.  Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. , 1995, Blood.

[12]  E. Solary,et al.  Der(16)t(1;16)(q10;p10) in multiple myeloma: a new non-random abnormality that is frequently associated with Burkitt's-type translocations. , 1995, Leukemia.

[13]  M. Taniwaki,et al.  Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. , 1994, Blood.

[14]  B. Barlogie,et al.  Deletion of the retinoblastoma gene in multiple myeloma. , 1994, Leukemia.

[15]  E. Wattel,et al.  Improved cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in multiple myeloma: a report on 46 patients , 1993, British journal of haematology.

[16]  S. Swerdlow,et al.  Chromosome 11 translocation breakpoints at the PRAD1/cyclin D1 gene locus in centrocytic lymphoma. , 1993, Leukemia.

[17]  R. Berger,et al.  Chromosome studies in plasma cell leukemia and multiple myeloma in transformation , 1992, Genes, chromosomes & cancer.

[18]  N. Harris,et al.  PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Delabie,et al.  Translocation (11;14): A cytogenetic anomaly associated with B‐cell lymphomas of non‐follicle centre cell lineage , 1991, The Journal of pathology.

[20]  L. Cro,et al.  Ras oncogene mutation in multiple myeloma , 1989, The Journal of experimental medicine.

[21]  I. Lisse,et al.  Occurrence and type of chromosomal abnormalities in consecutive malignant monoclonal gammopathies: correlation with survival. , 1988, Cancer genetics and cytogenetics.

[22]  B. Barlogie,et al.  Plasma Cell Karyotype in Multiple Myeloma , 1988 .

[23]  P. Bevan,et al.  Analysis of G banded karyotypes in myeloma cells. , 1986, Journal of clinical pathology.

[24]  R. Kyle,et al.  The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. , 1985, Blood.

[25]  Jerry P. Lewis,et al.  Non‐random chromosomal aberrations associated with multiple myeloma , 1984, Hematological oncology.

[26]  S. Raptis,et al.  Cytogenetic study in multiple myeloma. , 1984, Cancer genetics and cytogenetics.

[27]  K. Takatsuki,et al.  Cytogenetic studies and clinical aspects of patients with plasma cell leukemia and leukemic macroglobulinemia. , 1983, Cancer research.

[28]  B. Durie.  Staging and kinetics of multiple myeloma. , 1982, Seminars in oncology.

[29]  J. Rowley,et al.  Karyotypic abnormalities and clinical aspects of patients with multiple myeloma and related paraproteinemic disorders , 1979, Cancer.

[30]  E. Schuuring,et al.  The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene. , 1997, Blood.

[31]  K. Uchimaru,et al.  Overexpression of the PRAD1 oncogene in a patient with multiple myeloma and t(11;14)(q13;q32). , 1995, Acta haematologica.

[32]  D. Hossfeld,et al.  Karyotype in multiple myeloma and plasma cell leukaemia. , 1993, European journal of cancer.

[33]  C. Mecucci,et al.  Translocation t(11;14) and trisomy 11q13----qter in multiple myeloma. , 1984, Annales de genetique.